Specific usage and dosage guidance of ernatumumab

The use of Elranatamab (Elranatamab) is highly standardized. To ensure treatment safety and maximum benefit, its dosage regimen is precisely divided into an ascending dose phase and a maintenance treatment phase. This drug is only allowed for subcutaneous injection, not intravenous or intramuscular administration. Special attention should be paid to cytokine release syndrome (CRS) and neurotoxic reactions (ICANS) in the early stage of use, so the first two incremental doses need to be closely monitored in the hospital.

The initial treatment phase is divided into three steps: 12mg is injected subcutaneously on the 1st day (incremental dose 1), 32mg is injected on the 4th day (increasing dose 2), and the first treatment dose of 76mg is given on the 8th day. This phase is designed to gradually activate T cells and reduce the risk of a violent immune system reaction. Patients need to be hospitalized for observation in a medical institution for 48 hours after the first dose and 24 hours after the second dose to ensure safety monitoring.

The maintenance treatment phase will be entered from day . From day 9 to week 24, 76mg will be injected subcutaneously once a week. If the patient has no obvious toxic reactions during the first 24 weeks of treatment and the efficacy is stable, the frequency can be adjusted to once every two weeks after the 25th week and continued until the disease progresses or unacceptable adverse reactions occur. The setting of this stage reflects eractuzumab’s high focus on quality of life while ensuring efficacy.

All treatments must be conducted under the guidance of doctors with experience in tumor immunotherapy. It is recommended to complete infection screening, complete blood count and organ function assessment before treatment. During treatment, patients need to be closely monitored for symptoms of CRS (such as fever, hypotension, etc.) and neurological reactions. If there is an obvious toxic reaction, administration must be delayed or treatment must be interrupted in a timely manner according to the severity.

Overall, the dosage regimen of eractuzumab in the treatment of multiple myeloma is scientific and rigorous, ensuring efficacy while taking into account patient safety and convenience of life, providing a trustworthy standard path for late-line treatment of multiple myeloma.

Reference materials:https://www.drugs.com/mtm/elranatamab.html